SecSonar.com

ProQR Therapeutics N.V. (PRQR)

ProQR Therapeutics N.V. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

ProQR Therapeutics N.V. (PRQR) is a Biotechnology company based in NL with a market capitalization of $168.6M. Revenue declined 19.2% year-over-year and free cash flow was negative at -$59.1M. This page tracks PRQR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

NL · 166 employees · IPO Sep 18, 2014

Valuation

Valuation & price

$1.59 · as of May 17, 2026 · -47.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.42

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.95$2.16$1.37Jul 25Dec 25Jul 26Jul 7, 25$2.14Jul 9, 25$2.30Jul 11, 25$2.32Jul 15, 25$2.36Jul 17, 25$2.40Jul 21, 25$2.34Jul 23, 25$2.17Jul 25, 25$2.23Jul 29, 25$2.19Jul 31, 25$2.10Aug 4, 25$2.07Aug 6, 25$2.06Aug 11, 25$1.89Aug 13, 25$2.02Aug 15, 25$2.05Aug 19, 25$2.03Aug 21, 25$2.21Aug 25, 25$2.25Aug 27, 25$2.21Aug 29, 25$2.25Sep 3, 25$2.43Sep 5, 25$2.45Sep 9, 25$2.33Sep 11, 25$2.19Sep 16, 25$1.99Sep 18, 25$2.19Sep 22, 25$2.16Sep 24, 25$2.10Sep 26, 25$2.11Sep 30, 25$2.13Oct 2, 25$2.25Oct 6, 25$2.36Oct 8, 25$2.36Oct 10, 25$2.41Oct 14, 25$2.46Oct 16, 25$2.80Oct 21, 25$2.95Oct 23, 25$2.82Oct 27, 25$2.86Oct 29, 25$2.65Oct 31, 25$2.75Nov 4, 25$2.38Nov 6, 25$2.21Nov 10, 25$2.16Nov 12, 25$2.16Nov 14, 25$2.17Nov 18, 25$2.08Nov 20, 25$2.06Nov 25, 25$2.15Nov 28, 25$2.34Dec 2, 25$1.95Dec 4, 25$2.12Dec 8, 25$2.12Dec 10, 25$2.23Dec 12, 25$2.33Dec 16, 25$2.27Dec 18, 25$2.10Dec 22, 25$2.14Dec 24, 25$2.17Dec 29, 25$2.04Jan 2, 26$1.99Jan 6, 26$2.08Jan 8, 26$2.10Jan 12, 26$1.68Jan 14, 26$1.64Jan 16, 26$1.65Jan 21, 26$1.64Jan 23, 26$1.75Jan 27, 26$1.68Jan 29, 26$1.60Feb 2, 26$1.55Feb 4, 26$1.55Feb 9, 26$1.47Feb 11, 26$1.42Feb 13, 26$1.46Feb 18, 26$1.49Feb 20, 26$1.44Feb 24, 26$1.51Feb 26, 26$1.59Mar 2, 26$1.58Mar 4, 26$1.70Mar 6, 26$1.78Mar 10, 26$1.80Mar 12, 26$1.72Mar 17, 26$1.77Mar 19, 26$1.59Mar 23, 26$1.55Mar 25, 26$1.58Mar 27, 26$1.37Mar 31, 26$1.62Apr 2, 26$1.71Apr 7, 26$1.70Apr 9, 26$1.98Apr 13, 26$1.80Apr 15, 26$1.99Apr 17, 26$1.99Apr 22, 26$1.75Apr 24, 26$1.55Apr 28, 26$1.48Apr 30, 26$1.57May 4, 26$1.64May 6, 26$1.72May 8, 26$1.58May 12, 26$1.60May 14, 26$1.65May 18, 26$1.51May 20, 26$1.43May 22, 26$1.56May 28, 26$1.57Jun 1, 26$1.42Jun 3, 26$1.47Jun 5, 26$1.50Jun 9, 26$1.47Jun 11, 26$1.44Jun 15, 26$1.56Jun 17, 26$1.67Jun 22, 26$1.88Jun 24, 26$1.81Jun 26, 26$1.53Jul 2, 26$1.78
$1.3752-week range$3.05
Loading valuation history…

Fundamentals

Key fundamentals

$168.6M

Market cap

-19.2%

Revenue growth (YoY)

83.0%

Gross margin

-$59.1M

Free cash flow (USD)

-$78.4M

Net debt

Net cash position

29.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$2.3MFY 2017$-1.5MFY 2018$4.9MFY 2019$1.9MFY 2020$1.0MFY 2021$1.3MFY 2022$3.6MFY 2023$6.5MFY 2024$18.9MFY 2025$15.3M
$2.3M$15.3M

Free cash flow by year

2016 → 2025

FY 2016$-36.8MFY 2017$-35.1MFY 2018$-31.0MFY 2019$-44.5MFY 2020$-48.0MFY 2021$-26.5MFY 2022$-69.2MFY 2023$20.2MFY 2024$-37.8MFY 2025$-51.7M
-$36.8M-$51.7M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202583.0%
100.0%83.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed Jun 2, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingPositive Phase 1 DataJun 25, 2026Filing
  • 6-K filingUnderwriting AgreementJun 25, 2026Filing
  • Annual reportAnnual Report FiledJun 2, 2026Filing
  • Annual reportAnnual Report FiledMay 12, 2026Filing
  • Annual reportAnnual Report FiledMay 12, 2026Filing
  • 6-K filing2026 Annual General Meeting AgendaMay 4, 2026Filing
  • 6-K filingManagement ChangeApr 30, 2026Filing
  • 6-K filingStrategic PartnershipApr 8, 2026Filing
  • 6-K filingInvestor & Analyst EventApr 8, 2026Filing

Questions

Frequently asked questions

What is ProQR Therapeutics N.V.'s market cap?

ProQR Therapeutics N.V. (PRQR) has a market capitalization of $168.6M.

What is PRQR's P/E ratio?

A meaningful P/E ratio is not available for PRQR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is PRQR's price-to-book (P/B) ratio?

PRQR trades at 3.42 times book value per share.

Are insiders buying PRQR stock?

SEC Form 4 filings show no open-market insider buys at ProQR Therapeutics N.V. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

PLX

Protalix BioTherapeutics, Inc.

$170.4M

SPRO

Spero Therapeutics, Inc.

$163.3M

ORMP

Oramed Pharmaceuticals Inc.

$162.9M

IFRX

InflaRx N.V.

$175.9M

VXRT

Vaxart, Inc.

$159.3M

UNCY

Unicycive Therapeutics, Inc.

$158.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.